Head to head
Immunocore vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: IMCR · VRTX
IMCR
Immunocore
29.41-0.47%
1-year price shape — -14% over the period
Quant Rating D · 24/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (67); Vertex Pharmaceuticals has done best over the past year (+23%); Vertex Pharmaceuticals earns the most per share.
| IMCR | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Biotechnology |
| Last price | 29.41 | 505.64 |
| Change today | -0.47% | +0.66% |
| 1-year return | -14.1% | +23.2% |
| Market cap | $1.51B | $128.16B |
| 52-week range | 27.56 – 40.71 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -79.49 | 29.45 |
| P/E percentile, own 5-yr range | 9th | 74th |
| P/B | 3.61 | 6.33 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.71 | 15.32 |
| Net profit (TTM) | $-36.56M | $3.88B |
| Revenue (TTM) | $430.78M | $12.59B |
| Revenue growth (YoY) | +18.3% | +12.5% |
| Gross margin | 98.9% | 86.0% |
| Operating margin | -5.2% | 37.9% |
| Net margin | -4.2% | 35.0% |
| Free cash flow (TTM) | $-41.15M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 102.1% | 97.2% |
| Insider activity (12mo) | 33 buy / 17 sell | 25 buy / 25 sell |
| Short interest (% of float) | 15.1% | 1.9% |
| Analyst consensus | 67% buy / 33% hold (6) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $63 (+114%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | D (24) | C (67) |
| Company | ||
| Employees | 524 | 6,400 |
| Founded | 2021 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.